ERBB2 and neoplasm: By chemically coupling recombinant sialidases to trastuzumab, human epidermal growth factor receptor 2 (HER2)-specific antibody-sialidase conjugates have been constructed to desialylate tumor cells in a HER2-dependent manner, thus disrupting the sialoside-SIGLEC axis and enhancing antibody-dependent cell-mediated cytotoxicity10,115.